Results 231 to 240 of about 124,423 (315)

Correction to "Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient ith the NUDT15 *1/*6 Genotype: A Brief Report". [PDF]

Clin Transl Sci
europepmc   +1 more source

An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia. [PDF]

Commun Med (Lond)
Krali O, Enblad AP, Sulyaeva J, Gogishvili D, Lundmark A, Harila A, Andersson C, Erkers T, Heinäniemi M, Lönnerholm G, Nordlund J.   +10 more
europepmc   +1 more source

A case report of soluble A antigen confounding the blood type in a haplo‐identical hematopoietic stem cell transplant patient with graft‐versus‐host disease

Transfusion, EarlyView.
Abstract Background ABO‐incompatible (ABOi) hematopoietic stem cell transplantation (HSCT) is often associated with ABO discrepancies post‐HSCT. Re‐emergence of the patient's original type post‐HSCT may signal graft loss, disease relapse, recent transfusion, or soluble ABO antigen.
Sheri Hugan, Nada Naiyer, Laura Cooling
wiley   +1 more source

Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence. [PDF]

Hematol Rep
Mohammed Saleh MF, Nasiri A, Abdrabou AK, Samarkandi H, Saad A, Aljurf M, Hanbali A, Alahmari A.   +7 more
europepmc   +1 more source

Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response

Transfusion, EarlyView.
Abstract Background Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of hematologic malignancies, but its success depends on obtaining sufficient CD3+ T‐cell yields during leukapheresis. This can be difficult in heavily pretreated patients, who often show leukopenia and reduced T‐cell fitness.
Hanna Kuhn, Felix Korell, Angela Hückelhoven‐Krauss, Brigitte Neuber, Miriam Stenzinger, Anita Ludwig‐Husemann, Maria‐Luisa Schubert, Patrick Derigs, Kiavasch Farid, Tim Sauer, Sandra Sauer, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt   +14 more
wiley   +1 more source

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

Transfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza, Thamy Silva, Mateus Domentino, Marina Conrado, João Oliveira, Elyse Moritz, Akemi Chiba, Vanderson Rocha, Alfredo Mendrone‐Junior, José Bordin, Langhi Dante, Carla Dinardo   +11 more
wiley   +1 more source

Dexamethasone for Chemotherapy‐Induced Nausea and Vomiting Prevention in Pediatric Patients: International Consensus

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Background An international Delphi panel of experts developed consensus statements to delineate the circumstances where the risks of dexamethasone as an antiemetic do and do not outweigh its benefits. Procedure Experts in supportive care of pediatric patients were invited to participate.
Negar Shavandi, Paula D. Robinson, Shana Jacobs, L. Lee Dupuis, the International Pediatric Dexamethasone Panel, Sameer Bakhshi, Tiene Bauters, Eva Brack, Simone Cesaro, Claire Fosbrook, Jason Freedman, Tamara MacDonald, Eloise Neumann, Venkatraman Radhakrishnan, Rod Rassekh, Florian Slimano, Johnathan Soggee, Joel Thompson, Marianne van de Wetering, Milena Villarroel, Jasper Wong   +20 more
wiley   +1 more source

Editorial: Advancing therapeutic strategies for relapsed/refractory acute lymphoblastic leukemia. [PDF]

Front Med (Lausanne)
Ebrahimi-Fakhari D, Tragiannidis A.
europepmc   +1 more source

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source